EASYWELL
易威生醫科技股份有限公司
EASYWELL is a Taiwan TPEx-listed biotechnology company; its most advanced asset is TLX-001 (FDA marketing authorization obtained, Cough), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| TLX-001 | — | FDA marketing authorization obtained | Cough | United States | — | Company disclosure |
| TLX-005 | — | FDA marketing authorization obtained | Overactive bladder | United States | — | Company disclosure |
| HH-001 | — | — | — | — | 2026-03-15 | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.